BioHemp (BKIT) Provides Guidance on Placing Trading Orders in Open Market

(NEW YORK)–BioHemp International (OTC:BKIT) is pleased to announce that as of Oct. 14, 2019 the company has begun the process to regain compliance to relist the company stock back current with OTC Markets.

The Company has retained a law firm that specializes specifically in assisting companies in filing 15c-211 to regain trading compliance, and feel we are heading in right direction now to correct this issue in the near future.

How to Trade BKIT Currently

Since BKIT security is listed on what they call the ‘Grey Sheets’ it has become a bit more difficult for investors to place buy and sell orders for execution, but still remains possible.

Grey Sheets mean our security currently does not have market makers representing bids and asks in the market, and thus all orders must be meet by matched trades among investors, individually.

Any investors interested in placing orders to buy or sell our security are advised to place limit orders as ‘good to cancel’ as this may assist market makers in placing orders on an unsolicited basis.

Most popular online platforms may still allow you to submit orders, but for ones that provide difficulty you may need to call in any orders directly by phone to your prospective brokerage firm.

Obviously establishing normal trading market is our first and highest priority, and we are working diligently to correct this issue as quick as possible. In meantime we felt it also important to form better communication and guidance to shareholders during these difficult times as we move forward.

Below are several ways to receive future updates on company:

Twitter: Investors can follow us on our official Twitter account, which we plan to use to keep followers updates on non-material events regarding the company. Users can follow us at

Mailing List: Investors can also join our investor mailing list to receive updates on news, and special announcements, and add their mailing list for future investor packets and brochures as we begin our marketing and advertisement campaigns. Users can join our mailing list by going to

Press Releases: We will also utilize press releases on national wire service to update investors on more major announcements like product launches, and new partnerships. Due to current trading issues though we expect to hold off on any major uses of press releases until we can reestablish our trading back “current” with OTC Markets.

8K Filings: We plan to utilize 8-k filings with SEC to disclose more material and important events.

New Team Members

During this time we will also be working to build up our team of advisers behind the company, which we intend to update in the coming weeks. You can visit our TEAM section of our website to get updates as new advisers are appointed.

About BioHemp International, Inc.

Located in New York City, BioHemp International is an early stage venture firm focused on establishing a portfolio of product brands, and distribution channels, for the growing cannabidiol (CBD) market. The Company’s management team holds years of experience in private equity, startup development, and financial consulting, which they plan to utilize in developing out future growth through strategic rollups and acquisitions.

Safe Harbor Notice

Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995) cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management, including the Company’s implementation of its business plan, the outcome of any investigation in the above-described matter, and the Company’s ability to succeed in the CBD market. Actual results could differ materially from current projections or implied results. BioHemp International, Inc., undertakes no obligation to revise these statements following the date of this news release. Additional details of the Company’s business can be found in its public disclosures as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.

Daniel Blum,
CEO & President

BioHemp International (OTC:BKIT)
244 5th Avenue Suite A-154
New York, NY 10001
Office: +1 (646) 453-4912
Cell: +1 (914) 806-1850

About author